169 related articles for article (PubMed ID: 17257497)
1. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange.
Geng SS; Feng J; Li Y; Sun Y; Gu X; Huang Y; Wang Y; Kang X; Chang H; Shen B
Cell Mol Immunol; 2006 Dec; 3(6):439-43. PubMed ID: 17257497
[TBL] [Abstract][Full Text] [Related]
2. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
3. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.
Shan D; Press OW; Tsu TT; Hayden MS; Ledbetter JA
J Immunol; 1999 Jun; 162(11):6589-95. PubMed ID: 10352275
[TBL] [Abstract][Full Text] [Related]
4. [Expression and Characterization of Single-chain Fv-Fc Fusion Protein against Human P185(erbB2)].
Xie ZG; Guo N; Shi M; Feng JN; Yu M; Sun YX; Shen BF
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):371-4. PubMed ID: 12673393
[TBL] [Abstract][Full Text] [Related]
5. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
6. The design, construction and function of a new chimeric anti-CD20 antibody.
Wang Y; Feng J; Huang Y; Gu X; Sun Y; Li Y; Shen B
J Biotechnol; 2007 May; 129(4):726-31. PubMed ID: 17433484
[TBL] [Abstract][Full Text] [Related]
7. Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO/dhfr- cells.
Cao M; Cao P; Yan H; Lu W; Ren F; Hu Y; Zhang S
Appl Biochem Biotechnol; 2009 Jun; 157(3):562-74. PubMed ID: 19099209
[TBL] [Abstract][Full Text] [Related]
8. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.
Hamdy N; Goustin AS; Desaulniers JP; Li M; Chow CS; Al-Katib A
J Immunol Methods; 2005 Feb; 297(1-2):109-24. PubMed ID: 15777935
[TBL] [Abstract][Full Text] [Related]
9. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
10. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
J Gastroenterol Hepatol; 2006 Sep; 21(9):1439-47. PubMed ID: 16911690
[TBL] [Abstract][Full Text] [Related]
12. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
13. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
14. Improved antigen binding by a CD20-specific single-chain antibody fragment with a mutation in CDRH1.
Adamson PJ; Millard DJ; Hohmann AW; Mavrangelos C; Macardle PJ; Pilkington G; Mulhern TD; Tedder TF; Zola H; Nicholson IC
Mol Immunol; 2006 Feb; 43(6):550-8. PubMed ID: 15936081
[TBL] [Abstract][Full Text] [Related]
15. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
[TBL] [Abstract][Full Text] [Related]
16. [Expression of ATR-Fc fusion protein in CHO cells].
Gao LH; Hu XW; Chen W; Xu JJ; Zhao J; Chen HP
Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):826-31. PubMed ID: 16285529
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional structures of single-chain Fv-neuraminidase complexes.
Malby RL; McCoy AJ; Kortt AA; Hudson PJ; Colman PM
J Mol Biol; 1998 Jun; 279(4):901-10. PubMed ID: 9642070
[TBL] [Abstract][Full Text] [Related]
18. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
[TBL] [Abstract][Full Text] [Related]
19. Enhanced intracellular stability of sFv-Fc fusion intrabodies.
Strube RW; Chen SY
Methods; 2004 Oct; 34(2):179-83. PubMed ID: 15312671
[TBL] [Abstract][Full Text] [Related]
20. A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells.
Kikuchi Y; Uno S; Yoshimura Y; Otabe K; Iida S; Oheda M; Fukushima N; Tsuchiya M
Biochem Biophys Res Commun; 2004 Mar; 315(4):912-8. PubMed ID: 14985099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
